STERIS PLC Surges to Top 429 in Trading Volume with $242 Million Turnover

On July 17, 2025, STERIS PLC (STE) saw a significant increase in trading volume, with a turnover of $242 million, marking a 92.61% rise from the previous day. This surge placed STERIS among the top 429 stocks by trading volume for the day. However, the stock price experienced a decline of 1.33%, marking the second consecutive day of losses, with a total decrease of 1.86% over the past two days.

STERIS PLC, headquartered in Mentor, Ohio, is a global provider of infection prevention products and services. The company operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. STERIS is scheduled to report its Q2 earnings on August 5, 2025. Analysts anticipate the company to report a profit of $2.32 per share, reflecting a 14.3% increase from the same quarter last year. STERIS has consistently met or exceeded Wall Street's earnings estimates in the past four quarters.

For the fiscal year 2025, analysts project STERIS to report earnings of $10.13 per share, an increase of 9.9% from $9.22 in fiscal 2024. Earnings are expected to rise further by 8.1% year-over-year to $10.95 per share in fiscal 2026. The company's stock has grown by 3.8% over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund’s 10.3% decline but lagging behind the S&P 500 Index's 10.9% gain.

Following the release of its Q4 earnings on May 14, 2025, STERIS reported a 4.3% increase in revenue to $1.5 billion, driven by strong growth in its Healthcare and AST segments. The company's adjusted EPS grew by 6.2% year-over-year to $2.74, surpassing consensus estimates by 5.8%. Analysts' consensus opinion on STERIS stock is highly optimistic, with an overall "Strong Buy" rating. Out of eight analysts covering the stock, six advise a "Strong Buy" rating and two recommend a "Hold." The stock's average analyst price target is $272.14, indicating an 18.9% potential upside from current levels.

STERIS has also been actively involved in strategic acquisitions. On June 21, 2023, the company announced its acquisition of a surgical instrumentation platform from BD, further expanding its product offerings and market presence. This acquisition is expected to enhance STERIS's capabilities in infection prevention and sterilization technologies, positioning the company for continued growth and innovation in the healthcare sector.